Abstract
ADAMTS4 (Aggrecanase-1) is an important enzyme, which belongs to ADAMTS family. Aggrecanase-1 is involved in aggrecan degradation of articular cartilage in osteoarthritis and rheumatoid arthritis. Overall variability of S1’ domain of ADAMTS4 has been the main selectivity determinant to design the unique inhibitors. 34 inhibitors from Binding database and literature were used to develop the pharmacophore model. The five featured pharmacophore model AHHRR had the best survival score of 3.493 and post-hoc score of 2.545, indicating that the model is highly reliable. The 3D-QSAR acquired had excellent r2 value of 0.99 and GH score of 0.839. The validated pharmacophore model was used for insilico screening of Asinex and ZINC database for finding the potential lead compounds. ZINC00987406 and ASN04459656 which pose high glide score i.e >7 Kcal/mol and H-bond and hydrophobic interactions in the S1‘loop residues of ADAMTS4 were subjected to Molecular Dynamics Simulation studies. Molecular dynamic simulation result indicates that the RMSD and RMSF of backbone atoms for the above complexes were within the limit of 2.0 A˚. These compounds can be potential candidates for osteoarthritis by inhibiting ADAMTS4.
Keywords: ADAMTS4, pharmacophore, enrichment studies, docking studies, 3D-QSAR, molecular dynamics.
Combinatorial Chemistry & High Throughput Screening
Title:Identification of Potent Virtual Leads Specific to S1’ Loop of ADAMTS4: Pharmacophore Modeling, 3D-QSAR, Molecular Docking and Dynamic Studies
Volume: 19 Issue: 3
Author(s): P. Rathi Suganya, Sukesh Kalva and Lilly M. Saleena
Affiliation:
Keywords: ADAMTS4, pharmacophore, enrichment studies, docking studies, 3D-QSAR, molecular dynamics.
Abstract: ADAMTS4 (Aggrecanase-1) is an important enzyme, which belongs to ADAMTS family. Aggrecanase-1 is involved in aggrecan degradation of articular cartilage in osteoarthritis and rheumatoid arthritis. Overall variability of S1’ domain of ADAMTS4 has been the main selectivity determinant to design the unique inhibitors. 34 inhibitors from Binding database and literature were used to develop the pharmacophore model. The five featured pharmacophore model AHHRR had the best survival score of 3.493 and post-hoc score of 2.545, indicating that the model is highly reliable. The 3D-QSAR acquired had excellent r2 value of 0.99 and GH score of 0.839. The validated pharmacophore model was used for insilico screening of Asinex and ZINC database for finding the potential lead compounds. ZINC00987406 and ASN04459656 which pose high glide score i.e >7 Kcal/mol and H-bond and hydrophobic interactions in the S1‘loop residues of ADAMTS4 were subjected to Molecular Dynamics Simulation studies. Molecular dynamic simulation result indicates that the RMSD and RMSF of backbone atoms for the above complexes were within the limit of 2.0 A˚. These compounds can be potential candidates for osteoarthritis by inhibiting ADAMTS4.
Export Options
About this article
Cite this article as:
Suganya Rathi P., Kalva Sukesh and Saleena M. Lilly, Identification of Potent Virtual Leads Specific to S1’ Loop of ADAMTS4: Pharmacophore Modeling, 3D-QSAR, Molecular Docking and Dynamic Studies, Combinatorial Chemistry & High Throughput Screening 2016; 19 (3) . https://dx.doi.org/10.2174/1386207319666160127111318
DOI https://dx.doi.org/10.2174/1386207319666160127111318 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Adaptive Immunity by the Neurotransmitter Norepinephrine
Current Immunology Reviews (Discontinued) Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Tuberculous Pericarditis
Current Cardiology Reviews Gammadelta T Lymphocytes Producing IFNγ and IL-17 in Response to Candida Albicans or Mycobacterial Antigens: Possible Implications for Acute and Chronic Inflammation
Current Medicinal Chemistry Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Editorial: Nailfold Capillaroscopy in Rheumatology
Current Rheumatology Reviews Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases
Current Pharmaceutical Design Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Editorial [Hot Topic: Analgesic Drug Discovery: Promising Future (Guest Editor: Anindya Bhattacharya)]
Current Pharmaceutical Biotechnology “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Targeting Strategies to Modulate the NF-κB and JNK Signal Transduction Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pathogenesis in Childhood Idiopathic Nephrotic Syndrome: An Update of Patchwork
Current Pediatric Reviews Therapies Targeting Innate Immunity for Fighting Inflammation in Atherosclerosis
Current Pharmaceutical Design Chemical Instability Determines the Biological Action of the Artemisinins
Current Medicinal Chemistry Influence of CD80 and CD86 Co-Stimulation in the Modulation of the Activation of Antigen Presenting Cells
Current Immunology Reviews (Discontinued) Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design Editorial (Thematic Issue: Rheumatic Diseases as the Fuel to Inflamm-aging)
Current Aging Science Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets